Congress Moves to Add Biotech to Outbound-Investment Regime

Posted 8/12/26

By targeting pharmaceutical licensing deals, joint ventures and equity investments with Chinese covered foreign persons, the bill reflects a broader Washington judgment that drug discovery, clinical development and biologics manufacturing are no longer purely commercial life-sciences activities but strategic capabilities that can create dependency, military-readiness and supply-chain risks.

This item is available in full to subscribers.

Please log in to continue

Log in